In vitro cytogenetic toxicity of sertraline

(1)

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/322519129

In vitro cytogenetic toxicity of sertraline

Presentation · January 2018 DOI: 10.13140/RG.2.2.16209.22888 CITATIONS 0 READS 109 6 authors, including:

Some of the authors of this publication are also working on these related projects:

Evaluation of the cytogenetical results of 4707 cases diagnosed with amniocentesis. Cukurova Medical Journal, 2011; 36(1-4): 8-14.View project

Genotoxicity and Oxidative Effects of SertralineView project Erman Salih Istifli

Cukurova University 20PUBLICATIONS 209CITATIONS SEE PROFILE Nesrin Çetinel Cukurova University 6PUBLICATIONS 19CITATIONS SEE PROFILE Rima Celik

Kilis 7 Aralik Üniversitesi

5PUBLICATIONS 2CITATIONS SEE PROFILE

Mehmet Tahir Hüsunet

Cukurova University

9PUBLICATIONS 7CITATIONS SEE PROFILE

All content following this page was uploaded by Erman Salih Istifli on 16 January 2018. The user has requested enhancement of the downloaded file.

(2)

2nd_{International Mediterranean Science and Engineering Congress (IMSEC 2017)} Çukurova University, Congress Center, October 25-27, 2017, Adana / TURKEY Pages: 130-130, Paper ID:440

2nd_{International Mediterranean Science and Engineering Congress (IMSEC 2017), October 25-27, 2017, Adana/Turkey}

130

(*) Corresponding author

In vitro cytogenetic toxicity of sertraline

Erman Salih İstifli

*

_{, Nesrin Çetinel, Rima Çelik, Mehmet Tahir Hüsunet,}

Hasan Basri İla, Osman Demirhan

Abstract

Sertraline (SRT) is an antidepressant agent used as a neuronal selective serotonin-reuptake inhibitor (SSRI). SRT blocks serotonin reuptake and increases serotonin stimulation of somatodendritic serotonin 1A receptor (5-HT_1AR) and terminal autoreceptors in the brain. Although numerous studies on SSRIs indicate that many of those agents possess genotoxic risk, the genotoxic effect of SRT in human peripheral blood lymphocytes has not been investigated so far. In the present study, the genotoxic potential of SRT was evaluated using cytokinesis-block micronucleus (CBMN) cytome assay in peripheral blood lymphocytes of healthy human subjects. In addition, biochemical parameters of total antioxidant status (TAS) and total oxidant status (TOS) were measured to quantitate oxidative stress. Human peripheral blood lymphocytes were exposed to four different concentrations (1.25, 2.5, 3.75 and 5 µg/mL) of SRT for 24- and 48-h treatment periods. In this study, SRT was not found to induce MN formation either in 24- or 48-h treatment periods. In contrast, SRT induced a concentration-dependent decrease (r= - 0.979, p ≤ 0.01) in the MN when it was present for the last 48 hr (48-h treatment) of the culture period. The application of various concentrations of SRT did not increase TAS levels in either 24- or 48-h treatment periods when compared to control. However, SRT caused significant oxidative stress in both 24- or 48-h treatment periods. The increase in TOS was potent as the positive control MMC at both treatment times. In addition, exposing cells to SRT caused significant decreases in the nuclear division index at 1.25, 2.50 and 3.75 µg/mL in 24-h and at the highest concentration (5 µg/mL) in 48-h treatment periods. Our results suggest that SRT may have nucleotoxic effect on cultured human peripheral blood lymphocytes.

Keywords: sertraline, oxidative stress, micronucleus, peripheral blood lymhocytes, nucleotoxicity

View publication stats View publication stats